| Name | Title | Contact Details |
|---|---|---|
Ravi Samavedam |
Chief Innovation Officer | Profile |
Ilya Vasserman |
Chief Information Officer | Profile |
Chris Robitaille |
Chief Technology Officer | Profile |
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
biopharmservices is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Shiel offers a comprehensive menu of test and diagnostic options through participating physicians and health care providers, and through our ever expanding Patient Service Center Network. Our full-service in-house pathology department performs GYN (Pap
Hepalink was established in 1998 and restructured in 2007 to be a limited liability company.
Spokane Inter Res Tech Ins is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.